Last reviewed · How we verify
TB006
At a glance
| Generic name | TB006 |
|---|---|
| Sponsor | TrueBinding, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease (PHASE2)
- A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease (PHASE2)
- TB006 Expanded Access (EA) Compassionate Use
- Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects (PHASE1)
- TB006 for Autism Spectrum Disorder (PHASE2)
- A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke (PHASE2)
- Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease (PHASE1, PHASE2)
- Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TB006 CI brief — competitive landscape report
- TB006 updates RSS · CI watch RSS
- TrueBinding, Inc. portfolio CI